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Abstract
Background—Colorectal cancer (CRC) is a leading cause of cancer mortality in American 
Indian and Alaska Native (AIAN) people, and incidence rates vary considerably among AIAN 
populations throughout the United States. Screening has the potential to prevent CRC deaths by 
detection and treatment of early disease or removal of precancerous polyps. Surveillance of CRC 
screening is critical to efforts to improve delivery of this preventive service, but existing CRC 
screening surveillance methods for AIAN are limited. The Government Performance and Results 
Act (GPRA) CRC screening clinical care measure provides data on CRC screening among AIAN 
populations.
Purpose—The aim of this study was to evaluate the accuracy of the GPRA measure for CRC 
screening (sensitivity, specificity, positive predictive value and negative predictive value), 
determine reasons for CRC screening misclassification (procedures noted as screening when they 
were actually diagnostic exams), and to suggest opportunities for improving surveillance for CRC 
screening nationwide for AIAN populations.
Methods—Medical record reviews (paper and electronic) were compared to the GPRA-reported 
CRC screening status for 1,071 patients receiving care at tribal health facilities. A total of 8 tribal 
health facilities (2 small, 3 medium, and 3 large) participated in the study from the Pacific Coast, 
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the Southwest, the Southern Plains, and Alaska IHS regions. Screening-eligible patients were 
identified using queries of the local electronic health record from January 2007 to December 2008, 
and medical chart reviews were completed at participating facilities from September 2008 to June 
2010.
Results—Among 545 patients classified as screened by the GPRA measure, 305 (56%, CI: 
52%-60%) had a false positive for screening as compared with medical record review. The overall 
sensitivity of the GPRA measure for CRC screening was 93% (CI=89%-95%) while specificity 
was 62% (CI: 59%-66%). The most common reasons for misclassification were for diagnostic or 
surveillance tests to be recorded as screening (67%), as well as medical record miscoding (18%) 
due to miscoding, charting errors, screenings performed outside the IHS, testing for a non-
screening purpose, and categorization of patients as screened when a test had been ordered but not 
actually completed.
Conclusions—This study found that the GPRA CRC screening clinical measure overestimates 
the true screening rate due to the inclusion of diagnostic and surveillance exams, especially 
colonoscopy, as well as misclassification errors. The results of this study suggest a need to more 
accurately use the ICD-9 diagnostic code V76.51, which was associated with frequent coding 
errors. In combination with other programmatic efforts that focus on screening average- risk, 
asymptomatic American Indian and Alaska Native persons, improving the coding used for CRC 
screening may help to more accurately detect decreases in AIAN CRC incidence and mortality.
Background
Colorectal cancer (CRC) is a leading cause of cancer mortality in American Indian and 
Alaska Native (AIAN) people.1 Among AIAN people overall incidence and death rates from 
CRC are similar to the United States (U.S.) White population.2 However, AIAN people are a 
geographically dispersed, heterogeneous population. Incidence rates of CRC among AIAN 
groups vary considerably throughout the U.S., with the highest rates found in Alaska (102.6 
per 100,000) and the Northern Plains (72.5 per 100,000), and the lowest in the Southwest 
U.S. (21.0 per 100,000).3 CRC presents in AIAN people with more advanced disease at 
diagnosis as compared to non-Hispanic Whites.3-6
In the U.S., CRC incidence and death rates for men and women of all races/ethnicities 
declined from 1997-2006, whereas CRC AIAN rates did not decline, except for incidence 
rates for AIAN men.7 Declining national trends in CRC incidence and mortality among 
adults 50 years and older have been largely attributed to increases in CRC screening.7-11 
Screening has the potential to prevent CRC by detection and removal of precancerous 
polyps in the colon and rectum, as well as detecting early cancer at less costly, more 
treatable stages.8,12-14 The most common screening options include tests that primarily 
detect cancer (stool tests) and those are more likely to detect cancer and precancerous 
growths, including flexible sigmoidoscopy and colonoscopy.15-17 The United States 
Preventive Services Task Force (USPSTF) recommends routine CRC screening for average-
risk men and women, ages 50-75, using annual high-sensitivity guaiac-based fecal occult 
blood tests (gFOBT) or immunochemical fecal occult blood tests (FIT); flexible 
sigmoidoscopy every five years combined with high-sensitivity fecal occult blood testing 
every three years; or colonoscopy every ten years. For adults aged 76 to 85, the USPSTF 
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does not recommend routine screening but acknowledges that there may be considerations 
that support screening in an individual patient or first-time screening for those who have not 
previously been screened.13,18
Surveillance of CRC screening is critical to efforts to improve delivery of this preventive 
service. States perform surveillance for selected types of cancer screening through the 
Behavioral Risk Factor Surveillance System (BRFSS). Using Healthy People 2010 
measures, BRFSS data from 2010 showed that 49% of AIAN respondents ages 50-75 had a 
colonoscopy within ten years compared with 62.5% of U.S. Whites.19 A similar percentage 
of AIAN (15%) over age 50 had used a blood stool test within the past year as U.S. Whites 
(11%).20 However, BRFSS has recognized limitations in rural AIAN populations due to 
poor phone penetrance in rural areas, the frequent use of cell phones as a primary household 
line, and the voluntary nature of its surveys.21,22 The AIAN screening rate remains far 
below the Healthy People 2020 target (based on National Health Interview Study data) of 
70.5% of adults being up-to-date with the USPSTF CRC screening recommendations.23
In 1993, the U.S. Congress enacted the Government Performance and Results Act (GPRA) 
to improve the program performance of federal agencies. The Indian Health Service (IHS) 
uses GPRA reporting to provide an assessment of the quality of healthcare delivered in the 
Indian health system on an annual basis. GPRA mandates the tracking and reporting of IHS 
clinical care measures to Congress and the Office of Management and Budget (OMB). The 
IHS GPRA measures were developed using the Health Effectiveness Data and Information 
Set (HEDIS) coding guidelines. There are currently 22 clinical GPRA measures reported by 
IHS, including diabetes, dental access and care, immunizations, cancer screening, behavioral 
health screening, cardiovascular disease prevention, and HIV screening. Specific 
benchmarks for each measure are set annually, and are used for quality improvement, 
performance measurement, public health care, epidemiology, and research. Tribal and 
Federal programs report IHS GPRA data through the Clinical Reporting System (CRS). This 
is a software application which extracts data out of the Resource Patient Management 
System (RPMS), the centralized electronic health record for the Indian Health Service.
The CRC screening measure was added as a GPRA performance measure in 2006, and 
remains the major source of national CRC screening prevalence data among AIAN. AIAN 
screening rates reported through GPRA have been increasing nationwide, from 22% in 2006 
to 46% in 2012. However, screening rates in 2012 vary considerably by IHS region from 
33% in the IHS Phoenix Area to 60% in the IHS Oklahoma Area.24 Although CRC 
incidence and mortality can be reduced substantially through screening and early detection, 
the AIAN CRC screening rate using USPSTF recommendations remains far lower than 
other screen-detectable cancers including breast and cervical cancer in this population.24
The aims of this study were to evaluate the accuracy of the GPRA measure for CRC 
screening, determine reasons for false positive and false negative GPRA CRC screening 
misclassification, and suggest opportunities for improving surveillance for CRC screening 
nationwide for AIAN populations.
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The CRC screening definition used for the IHS GPRA measure is based on diagnostic and 
procedure codes in the electronic medical record (RPMS). The numerator for the GPRA 
CRC screening measure included AIAN patients who received fecal occult blood tests or 
fecal immunochemical test during the report period, flexible sigmoidoscopy or double 
contrast barium enema (DCBE) in the past 5 years, or colonoscopy in the past 10 years. Use 
of DCBE as a screening test was included in the GPRA CRC screening measure until 2013 
when it was removed to bring the measure in line with changes in the national USPSTF 
recommendations. Additionally, until 2009, documented refusals in the past year also 
counted towards meeting the CRC screening clinical GPRA measure. Numerator codes for 
FOBT or FIT include Current Procedural Terminology (CPT) codes 82270, 82274, 89205, 
G0107, G0328, G0394, Logical Observation Identifier Names and Codes (LOINC) 
taxonomy, and site-populated taxonomy: BGP GPRA FOB TESTS. For flexible 
sigmoidoscopy the allowable codes include Procedure code 45.24, CPT 45330 through 
45345, and G0104. For DCBE the allowable codes include CPT or VRad 74280, G0106, 
and G0120. For colonoscopy the allowable codes include International Classification of 
Diseases, Ninth Revision (ICD-9) Purpose of Visit (POV) code V76.51, Procedure codes 
45.22, 45.23, 45.25, 45.42, 45.43 and CPT codes 44388 through 44394.
The denominator for the GPRA CRC screening measure includes all living active clinical 
patients (2 or more visits to a health facility within the previous 3 years) aged 51-80 residing 
in the service area during the reporting period. Denominator exclusions include a 
documented history of colorectal cancer or total colectomy with POV codes 153.*, 154.0, 
154.1, 197.5, V10.05, CPT codes G0213 through G0215, G0231, 44150 through 44151, 
44152, 44153, 44155 through 44158, 44210 through 44212, and procedure code 45.8.
In this study medical record review was defined as the gold standard for determining 
screening status. Medical record review included the review of electronic health records 
with keyword searches and document review as well as examination of paper records with 
review of progress notes and relevant reports. Screening tests were defined as tests ordered 
without presenting symptoms or signs. Non-screening tests were defined as tests ordered for 
diagnostic or surveillance purposes. Diagnostic testing was defined as testing due to the 
presence of symptoms or signs. Surveillance testing was defined as follow-up endoscopy for 
high risk patients, especially those with a history of adenomatous polyps, inflammatory 
bowel disease, or after colorectal cancer resection.
This analysis focused on two main outcomes, including: 1) the ability of the GPRA measure 
to serve as a predictor of true screening status as determined by chart review using 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
and 2) reasons for screening status misclassification, including errors due to miscoding, 
charting errors, screenings performed outside the IHS, testing for a non-screening purpose, 
and categorization of patients as screened when a test had been ordered but not actually 
completed.
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The study protocol was reviewed and approved by the Indian Health Service National 
Institutional Review Board (IRB) as well as the Alaska Area IRB, and had relevant tribal 
clearance in the participating IHS regions.
Outcome Measures and Statistical Analysis
A sample size of 8 IHS facilities was chosen to represent different tribal facility sizes and 
geographical distribution (see Figure 1). Eight tribal health facilities participated in the 
study: two sites in the Pacific Coast IHS region, two in the Southwest region, one in the 
Southern Plains region, and three in Alaska. Screening-eligible patients were identified 
using queries of the local electronic health record from 2007 to 2008, and medical chart 
reviews were completed at participating facilities from September 2008 to June 2010.
Patient records were selected at random from screened and unscreened groups using a 1:1 
ratio. A total of 150 patient charts at three large and three medium size facilities and 75 to 
100 patient charts at two small facilities were determined to be an appropriate sample size of 
charts to review to determine true CRC screening rates, assuming 80% power to detect a 
difference between GPRA classification and medical record classification and an alpha of 
0.05. Statistical analysis was performed with SPSS for Windows, Version 20.0 (IBM, 
Chicago, IL, USA). Proportions and confidence intervals were calculated for categorical 
data. Binomial tests were used to calculate confidence intervals for the sensitivity and 
specificity of the GPRA measure using the results of the medical chart review as the gold 
standard.
Results
General patient demographics and clinical characteristics are shown in Table 1. The mean 
patient age was 60.3 years and the male to female ratio was approximately 2:3. The majority 
of patients (42%) were from Alaska, 23% were from the Southwest, 21% were from the 
Pacific Coast, and 14% were from the Southern Plains. A total of 29 patients (3%) had a 
family history of colorectal neoplasia, 92 (9%) had a personal history of adenomatous 
polyps, and 40 (4%) had a personal history of colorectal neoplasia documented in the 
medical record, all of which contribute to an increased risk of CRC warranting more 
frequent screening and/or surveillance.
Among 545 patients classified as screened by the GPRA measure, 305 (56%, CI: 52%-60%) 
had a false positive for screening as compared with medical record review. The overall 
sensitivity of the GPRA measure for CRC screening was 93% (CI=89%-95%) while 
specificity was 62% (CI: 59%-66%) (Table 2). Sensitivity and specificity were not 
significantly different when refusals were removed from the analysis. Of 545 patients 
screened according to the GPRA measure, 240 were screened according to chart review 
yielding a positive predictive value of 44% (CI: 40%-48%). Of 526 unscreened per the 
measure, 507 were unscreened by chart review, yielding a negative predictive value of 99% 
(CI: 97%-99%).
The most common reason for misclassification was for diagnostic or surveillance tests to be 
recorded as screening (67%) (Table 1). The next most common reason for misclassification 
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was miscoding as another type of procedure (18%), followed by tests that were ordered but 
not completed (8%), tests that were not captured as screening by the electronic health record 
(6%), and tests that were done outside the facility (2%). The use of the code V76.51 was 
especially prone to error, resulting in 96% of all miscoding occurrences. According to the 
GPRA measure, the most frequent screening type was colonoscopy. However, on medical 
record review which corrected GPRA misclassifications, the most frequent actual screening 
type was fecal occult blood testing. While the majority of fecal occult blood tests (78%) 
were determined in chart review to be for screening purposes, the majority of colonoscopies 
(64.9%) were found to be for diagnostic or surveillance purposes. Flexible sigmoidoscopy 
and double contrast barium enemas (DCBE) were infrequently used tests. There were no 
significant differences in GPRA misclassification by sex or IHS facility, but there was 
greater misclassification among patients over age 60, primarily due to a higher proportion of 
diagnostic and surveillance colonoscopies completed within this age group (data not shown).
Conclusions
To our knowledge, this is the first formal evaluation of an IHS GPRA clinical measure in 
comparison with medical chart review and RPMS review, and is unique in assessing how 
many patients captured in the GPRA numbers were truly receiving CRC screening versus 
diagnostic or follow-up tests. Many IHS tribal health facilities perform periodic data quality 
assurance audits to compare medical charts to the RPMS record. Additionally, several 
studies have examined the accuracy of specific diagnostic codes in the RPMS as compared 
to patient chart review, including conditions such as cervical cancer, obesity, and diabetes 
mellitus.25-28
This study found that the GPRA CRC screening clinical measure overestimates the true 
screening rate due to the inclusion of diagnostic and surveillance exams, especially 
colonoscopy procedures, as well as misclassification errors due to miscoding or categorizing 
patients as screened when a test had been ordered but not actually completed. There are 
several potential reasons why GPRA measures could be inaccurate: 1) an incorrect code is 
used such that the patient is not included in the numerator (miscoding), 2) screening 
information is not documented in RPMS; tests are sent to an outside facility for analysis and 
the results are not then entered into the facility medical record system; or the information is 
not yet entered into RPMS (data entry errors), or 3) the name of the test, especially for lab 
tests, is different than the site GPRA taxonomy and so is not included in the measure 
(incorrect taxonomy). The use of the code V76.51 was especially prone to error, resulting in 
the majority of all miscoding occurrences. This ICD-9 code is literally read as “special 
screening for malignant neoplasm of the colon.” With such a broad definition, coders use 
V76.51 for all of the types of screening tests with their different time intervals. GPRA 
however misinterprets this code as specifying colonoscopy suitable for 10 years, even if the 
actual screening was fecal occult blood testing which is only good for one year. These 
miscoding errors result in the GPRA measure showing patients as screened when in fact 
their screening is out of date. Overall the GPRA measure has a high sensitivity and negative 
predictive value, but a relatively low specificity and positive predictive value.
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This study was subject to the following limitations. First, AIAN people access healthcare at 
multiple locations, so a patient's screening status at one facility might under represent their 
true screening status. However, this study focused on the accuracy of the GPRA measure, 
not on attempting to characterize screening prevalence. Second, the selected sites might not 
represent all IHS sites. However, the results at each site were similar, despite varying size 
and geographical distribution. Third, diagnostic and surveillance testing serve the screening 
function in most patients, even if not intended for screening, so contribute to understanding 
overall CRC screening trends in the AIAN population.
The results of this study suggest a need to more accurately use the ICD-9 diagnosis code 
V76.51, which was associated with frequent coding errors. Because this code does not 
distinguish one screening modality from another, it is not possible to ascertain the proper 
timeframe for the measure. Additional training for coders across the Indian Health Service is 
recommended to help reduce GPRA misclassification errors. In 2012, the V76.51 code was 
removed from HEDIS, as well as from the GPRA CRC measure for 2013. Miscoding also 
plays a role in automated RPMS reminders for screening, which can often be out-of-date. 
Caution is needed in interpreting the GPRA measure in the patient care setting, as many 
patients had a history of polyps and/or a family history of CRC, both of which require more 
frequent follow-up than GPRA intervals for the average risk population. Also, screening 
results could be entered into RPMS only after a screening test has been completed, to reduce 
the chance of recording tests that are ordered but not completed, or tests that require a 
change in the initial test order codes. It is also important to periodically audit RPMS 
reminders to make sure they coincide with actual screening. Addressing these issues could 
affect billing and reimbursement, provide quality improvement for the medical record, as 
well as improve the accuracy of GPRA for tracking screening rates at IHS facilities. Lastly, 
exploring alternative tools to the GPRA measure, such as oversampling AIAN in 
population-based surveys based on self report may help to better quantify the true CRC 
screening rate in AIAN populations.
CRC screening has been increasing substantially throughout IHS regions nationwide due to 
multiple intervention campaigns and greater emphasis by tribal providers on the benefits of 
early screening. Many providers in the IHS are embracing the idea to encourage universal 
use of fecal occult blood testing. Various centers are considering newer FOBT approaches 
such as the immunochemical FOBT that are more sensitive and sometimes require fewer 
samples for testing than the older guaiac-based FOBT.29-33 The IHS has also created a 
strategic plan to increase CRC screening among AIAN populations, which focuses on four 
priority areas: 1) Health care professional education and practice, 2) Public education and 
awareness, 3) Health policy, and 4) Screening capacity.34 Many activities are occurring 
within each of these areas, including trainings for tribal community health providers, 
development of health education materials for community members, convening regional IHS 
CRC summit meetings, conducting stool test research studies in tribal areas, and exploring 
ways to increase tribal member access to screening in rural and urban areas.35-38 The impact 
of these combined efforts may be seen through a possible increase in AIAN CRC screening 
rate trends. Understanding the factors that impact the GPRA clinical measure for CRC 
screening, as well as making improvements in the GPRA measure will help IHS and tribal 
organizations to better evaluate the impact of CRC prevention and control activities.
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Map of Government Performance and Results Act (GPRA) validation study sites, 
2008-2010.
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Table 1





        Male 461 (43.0)
        Female 607 (56.7)
Age, y
    45-50 15 (1.4)
    51-60 573 (54.1)
    61-70 319 (30.1)
    71-80 153 (14.4)
Region
    Southern Plains 150 (14.0)
    Southwest 241 (22.5)
    Pacific Coast 227 (21.2)
    Alaska 453 (42.3)
Family history of CRC 29 (2.7)
Personal history of polyps 92 (8.6)
Personal history of CRC 40 (3.7)
GPRA misclassification 305 (56.0)
Refusal misclassification 12 (35.3)
Reasons for misclassification (n=328)
    Tested for non-screening purposes (diagnostic/surveillance) 219 (66.5)
    Miscoding 59 (18.0)
    Ordered but not done 25 (7.6)
    Not captured by EHR 18 (5.5)
    Done outside of facility/other 8 (2.4)
Screening indication captured by GPRA measure (n=458)
    DCBE 2 (11.8)
    Colonoscopy 325 (35.1)
    Flexible sigmoidoscopy 43 (76.7)
    FOBT 88 (78.4)
CRC, colorectal cancer; EHR, electronic health record; DCBE, double contrast barium enema; FOBT, fecal occult blood test.
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Table 2
Sensitivity and specificity of Government Performance and Results Act (GPRA) measure for detection of 
CRC screening
No. (%) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Screening including refusals as screened 1071 93 (89 - 95) 62 (59 - 66) 44 (40 - 48) 96 (94 - 98)
Screening with refusals not counted as 
screened
1071 97 (93 - 99) 61 (58 - 65) 40 (36 - 44) 99 (97 - 99)
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